EvlaBio secures €21 million in seed funding
EvlaBio closed a €21 million seed funding to complete preclinical development of a monoclonal antibody for the treatment of left ventricular hypertrophy in the setting of chronic ...
Read More
EvlaBio closed a €21 million seed funding to complete preclinical development of a monoclonal antibody for the treatment of left ventricular hypertrophy in the setting of chronic ...
Read More
Comphya SA, a Lausanne-based company pioneering the first implantable neurostimulation therapy for erectile dysfunction (ED) unresponsive to medication, has closed an oversubscrib...
Read More
Following the successful completion of the wefox’s business restructuring program, the insurtech company secured EUR 151 million. This consisted of a EUR 76 million capital raise ...
Read More
NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, has closed its Series B financing round led by Kurma Growth Opportunities Fun...
Read More
Our CEO, Joanne Sieber, recently sat down with the influential Swiss newspaper Le Temps to discuss a critical challenge for the nation’s future: financing the growth of our most promising deep tec...
Read More